PBYI

3.59

4.66% 0.16

Dopo l'orario di chiusura: 3.45 -0.14 -3.90%

Puma Biotechnology Inc (PBYI)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$3.43

Aprire:

$3.45

Volume 24 ore:

585.99K

Relative Volume:

1.68

Capitalizzazione di mercato:

$178.70M

Reddito:

$230.47M

Utile/perdita netta:

$30.28M

Rapporto P/E:

5.8852

EPS:

0.61

Flusso di cassa netto:

$38.86M

1 W Prestazione:

+6.85%

1M Prestazione:

+9.45%

6M Prestazione:

+17.70%

1 anno Prestazione:

+9.45%

Intervallo 1D:

$3.44

$3.65

Intervallo di 1 settimana:

$3.25

$3.65

Portata 52W:

$2.225

$4.13

Puma Biotechnology Inc Stock (PBYI) Company Profile

Nome

Puma Biotechnology Inc

Settore

Healthcare (1166)

Industria

Biotechnology (655)

Telefono

(424) 248-6500

Indirizzo

10880 WILSHIRE BLVD., LOS ANGELES, CA

Dipendente

172

Cinguettio

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

PBYI's Discussions on Twitter

Confronta PBYI con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
PBYI Puma Biotechnology Inc	3.59	178.70M	230.47M	30.28M	38.86M	0.61
VRTX Vertex Pharmaceuticals Inc	452.16	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	534.91	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	322.06	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	542.47	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	245.16	28.51B	3.81B	-644.79M	-669.77M	-6.24

Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2021-09-28	Aggiornamento	Citigroup	Neutral → Buy
2020-06-25	Ripresa	BofA/Merrill	Underperform
2019-10-08	Downgrade	Goldman	Neutral → Sell
2019-05-10	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2019-05-10	Downgrade	Citigroup	Buy → Neutral
2019-01-17	Iniziato	Leerink Partners	Mkt Perform
2019-01-03	Downgrade	Guggenheim	Buy → Neutral
2018-11-19	Aggiornamento	Goldman	Sell → Neutral
2018-11-02	Downgrade	BofA/Merrill	Buy → Underperform
2018-11-02	Downgrade	JP Morgan	Neutral → Underweight
2018-10-01	Iniziato	Cantor Fitzgerald	Overweight
2018-09-17	Iniziato	Goldman	Sell
2018-05-11	Reiterato	Stifel	Buy
2017-11-10	Reiterato	Citigroup	Buy
2017-11-10	Reiterato	RBC Capital Mkts	Sector Perform
2017-10-02	Reiterato	Stifel	Buy
2017-09-11	Reiterato	Credit Suisse	Outperform
2017-07-10	Ripresa	Leerink Partners	Outperform
2017-06-06	Reiterato	RBC Capital Mkts	Sector Perform
2017-05-25	Reiterato	RBC Capital Mkts	Sector Perform
2017-03-02	Reiterato	RBC Capital Mkts	Sector Perform

Mostra tutto

Puma Biotechnology Inc Borsa (PBYI) Ultime notizie

Jun 13, 2025

Puma Biotechnology Holds Annual Stockholders Meeting 2025 - TipRanks

Jun 13, 2025

Jun 11, 2025

Should Value Investors Buy Puma Biotechnology (PBYI) Stock? - Yahoo Finance

Jun 11, 2025

Jun 10, 2025

With 57% ownership, Puma Biotechnology, Inc. (NASDAQ:PBYI) boasts of strong institutional backing - Yahoo Finance

Jun 10, 2025

Jun 08, 2025

Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Sold by Squarepoint Ops LLC - Defense World

Jun 08, 2025

Jun 06, 2025

78,653 Shares in Puma Biotechnology, Inc. (NASDAQ:PBYI) Purchased by Mackenzie Financial Corp - Defense World

Jun 06, 2025

Jun 05, 2025

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)June 4, 2025 - BioSpace

Jun 05, 2025

Jun 04, 2025

Puma Biotechnology Awards Key Talent with 18,250 RSUs in Strategic Retention Move - Stock Titan

Jun 04, 2025

May 28, 2025

Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors - sharewise

May 28, 2025

May 26, 2025

Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now? - Yahoo Finance

May 26, 2025

May 20, 2025

Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Fly 25% But Investors Aren't Buying For Growth - simplywall.st

May 20, 2025

May 17, 2025

Is Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Latest Stock Performance A Reflection Of Its Financial Health? - simplywall.st

May 17, 2025